BRPI0510862A - medicamento para tratar disfunção sexual em um paciente, medicamento para tratar disfunção erétil em um paciente, medicamento para diminuir os efeitos colaterais associados com os agentes terapêuticos para tratar a disfunção sexual em um paciente, método para fabricação de um medicamento para tratamento da disfunção sexual de um paciente responsivo marginalmente ao inibidor de pde5, e uso do peptìdeo ac-nle-ciclo (-asp-his-d-phe-arg-trp-lys) -0h na perparação de um medicamento - Google Patents

medicamento para tratar disfunção sexual em um paciente, medicamento para tratar disfunção erétil em um paciente, medicamento para diminuir os efeitos colaterais associados com os agentes terapêuticos para tratar a disfunção sexual em um paciente, método para fabricação de um medicamento para tratamento da disfunção sexual de um paciente responsivo marginalmente ao inibidor de pde5, e uso do peptìdeo ac-nle-ciclo (-asp-his-d-phe-arg-trp-lys) -0h na perparação de um medicamento

Info

Publication number
BRPI0510862A
BRPI0510862A BRPI0510862-4A BRPI0510862A BRPI0510862A BR PI0510862 A BRPI0510862 A BR PI0510862A BR PI0510862 A BRPI0510862 A BR PI0510862A BR PI0510862 A BRPI0510862 A BR PI0510862A
Authority
BR
Brazil
Prior art keywords
patient
medicine
treat
sexual dysfunction
treat sexual
Prior art date
Application number
BRPI0510862-4A
Other languages
English (en)
Inventor
Lisa E Diamond
Dennis C Earle
Annette M Shadiack
Shubh D Sharma
Carl Spana
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of BRPI0510862A publication Critical patent/BRPI0510862A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MEDICAMENTO PARA TRATAR DISFUNçãO SEXUAL EM UM PACIENTE, MEDICAMENTO PARA TRATAR DISFUNçãO ERéTIL EM UM PACIENTE, MEDICAMENTO PARA DIMINUIR OS EFEITOS COLATERAIS ASSOCIADOS COM OS AGENTES TERAPêUTICOS PARA TRATAR A DISFUNçãO SEXUAL EM UM PACIENTE, MéTODO PARA FABRICAçãO DE UM MEDICAMENTO PARA TRATAMENTO DA DISFUNçãO SEXUAL EM UM PACIENTE RESPONSIVO MARGINALMENTE AO INIBIDOR DE PDE-5, E USO DO PEPTIDEO AC-NLE-CICLO (-ASP-HIS-D-PHE-ARG-TRP-LYS) -OH NA PREPARAçãO DE UM MEDICAMENTO. Refere-se a presente invenção a uma terapia de agente múltiplo para tratamento da disfunção sexual, incluindo a disfunção erétil masculina, com administração seqüencial de um tipo de inibidor fosfodiesterase V (PDE-5), tal como sildenafil, preferivelmente quando o inibidor de PDE-5 for administrado por meio de uma dose oral, e um agonista receptor de melanocortina 3 e/ou 4, tal como Ac-Nle-ciclo(-Asp-His-D-Phe-Arg-Trp-Lys) -OH (PT-141), preferivelmente quando o PT-141 for formulado para e administrado por meio intranasal e, adicionalmente, preferido quando o inibidor de PDE-5 for administrado antes de PT-141.
BRPI0510862-4A 2004-05-27 2005-05-27 medicamento para tratar disfunção sexual em um paciente, medicamento para tratar disfunção erétil em um paciente, medicamento para diminuir os efeitos colaterais associados com os agentes terapêuticos para tratar a disfunção sexual em um paciente, método para fabricação de um medicamento para tratamento da disfunção sexual de um paciente responsivo marginalmente ao inibidor de pde5, e uso do peptìdeo ac-nle-ciclo (-asp-his-d-phe-arg-trp-lys) -0h na perparação de um medicamento BRPI0510862A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57508204P 2004-05-27 2004-05-27
US11/139,730 US7235625B2 (en) 1999-06-29 2005-05-26 Multiple agent therapy for sexual dysfunction
PCT/US2005/018739 WO2005117935A1 (en) 2004-05-27 2005-05-27 Multiple agent therapy for sexual dysfunction

Publications (1)

Publication Number Publication Date
BRPI0510862A true BRPI0510862A (pt) 2007-12-26

Family

ID=35462732

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510862-4A BRPI0510862A (pt) 2004-05-27 2005-05-27 medicamento para tratar disfunção sexual em um paciente, medicamento para tratar disfunção erétil em um paciente, medicamento para diminuir os efeitos colaterais associados com os agentes terapêuticos para tratar a disfunção sexual em um paciente, método para fabricação de um medicamento para tratamento da disfunção sexual de um paciente responsivo marginalmente ao inibidor de pde5, e uso do peptìdeo ac-nle-ciclo (-asp-his-d-phe-arg-trp-lys) -0h na perparação de um medicamento

Country Status (8)

Country Link
US (1) US7235625B2 (pt)
EP (1) EP1755638A4 (pt)
JP (1) JP2008500369A (pt)
KR (1) KR20070036079A (pt)
AU (1) AU2005249474A1 (pt)
BR (1) BRPI0510862A (pt)
CA (1) CA2568218A1 (pt)
WO (1) WO2005117935A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0602397C1 (pt) * 2006-04-20 2009-11-24 Unicamp composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
AU2009257631B2 (en) * 2008-06-09 2014-07-24 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for treatment of sexual dysfunction
US20100104624A1 (en) * 2008-06-11 2010-04-29 Peter Langecker Combination therapy using phosphodiesterase inhibitors
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
MX2011013117A (es) * 2009-06-08 2012-05-23 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina.
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2011063366A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
CA2781405A1 (en) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Melanocortin-1 receptor-specific linear peptides
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
JP6567971B2 (ja) 2012-11-05 2019-08-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. 女性性機能障害の治療におけるブレメラノチドの使用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674839A (en) 1987-05-22 1997-10-07 Competitive Technologies, Inc. Cyclic analogs of alpha-MSH fragments
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
DE69429768T2 (de) 1993-04-05 2002-09-19 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5698560A (en) 1995-03-01 1997-12-16 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
WO2002064091A2 (en) 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
UA46166C2 (uk) 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
HUP0100705A3 (en) * 1997-12-16 2001-12-28 Pfizer Prod Inc Combination effective for the treatment of impotence
CN1134442C (zh) 1998-04-20 2004-01-14 美国辉瑞有限公司 吡唑并嘧啶酮cGMP PDE5抑制剂、其制备方法及用途及中间体
AU3768799A (en) 1998-04-28 1999-11-16 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
AU5995699A (en) 1998-10-23 2000-05-15 Bunnage, Mark Edward Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
WO2000053148A2 (en) 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
KR100558131B1 (ko) 1999-03-29 2006-03-10 더 프록터 앤드 갬블 캄파니 멜라노코르틴 수용체 리간드를 함유하는 약제학적 조성물및 멜라노코르틴 수용체 리간드를 함유하는 약제의제조방법
US7258850B2 (en) 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6579968B1 (en) 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
AU5874200A (en) 1999-08-12 2001-03-13 Palatin Technologies, Inc. Melanocortin metallopeptide constructs, combinatorial libraries and applications
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU7547900A (en) 1999-10-11 2001-04-23 Pfizer Inc. 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo(4,3-d)pyrimidin-7-ones as phosphodiesterase inhibitors
AU6497701A (en) 2000-05-30 2001-12-11 Merck & Co Inc Melanocortin receptor agonists
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6892568B2 (en) 2003-02-03 2005-05-17 Honda Giken Kogyo Kabushiki Kaisha Noise detection system and method
CA2439691A1 (en) 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
JP2004534851A (ja) 2001-07-11 2004-11-18 パラチン テクノロジーズ インク． メラノコルチン受容体に特異的な線状および環状ペプチド
CA2473036A1 (en) 2002-01-23 2003-07-31 Paul Leslie Ornstein Melanocortin receptor agonists
AU2003248888A1 (en) 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
WO2005079574A1 (en) 2004-01-21 2005-09-01 Palatin Technologies, Inc. Bicyclic melanocorin-specific compounds

Also Published As

Publication number Publication date
US7235625B2 (en) 2007-06-26
WO2005117935A1 (en) 2005-12-15
AU2005249474A1 (en) 2005-12-15
EP1755638A1 (en) 2007-02-28
KR20070036079A (ko) 2007-04-02
JP2008500369A (ja) 2008-01-10
EP1755638A4 (en) 2009-07-29
US20050222014A1 (en) 2005-10-06
CA2568218A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
BRPI0510862A (pt) medicamento para tratar disfunção sexual em um paciente, medicamento para tratar disfunção erétil em um paciente, medicamento para diminuir os efeitos colaterais associados com os agentes terapêuticos para tratar a disfunção sexual em um paciente, método para fabricação de um medicamento para tratamento da disfunção sexual de um paciente responsivo marginalmente ao inibidor de pde5, e uso do peptìdeo ac-nle-ciclo (-asp-his-d-phe-arg-trp-lys) -0h na perparação de um medicamento
DE60022021D1 (de) Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion
ES2904543T3 (es) Tratamiento de la disfunción sexual
JP2004091490A (ja) 勃起機能不全の治療のためのｃＧＭＰ−ＰＤＥ阻害薬
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR037183A1 (es) Formulacion de liberacion controlada para administracion por via oral que proporciona un rapido inicio de alivio para el ansia de nicotina y uso de un componente de liberacion oral de nicotina y un componente de liberacion de nicotina en el tracto gastrointestinal para prepararla
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
ES2296781T3 (es) Metodo para el tratamiento de la artritis reactiva o de la bursitis.
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
US9125911B2 (en) Combined systemic and topical treatment of disordered tissues
PT1251850E (pt) Utilizacao de uma preparacao de combinacao na terapia do cancro
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
CN104069265A (zh) 一种治疗阳痿的中药酒及其制备方法
AR068514A1 (es) Aztreonam lisina inhalada para el tratamiento de deficits de salud relacionados con la calidad de vida (cvrs) de las enfermedades pulmonares
Hamilton et al. ALTERATIONS IN RESPONSE TO SOMATIC PAIN ASSOCIATED WITH ANAESTHESIA: XVIII: STUDIES WITH SOME OPIATE ANTAGONISTS
Winkelman et al. Prostigmin in the Treatment of Myasthenia Gravis and Muscular Dystrophy: Results Obtained with Divided Doses
CN104324018A (zh) 广藿香醇在制备男性性功能障碍药物或保健品中的应用
Patel et al. Use of transdermal gel of sildenafil citrate in sexual dysfunction
AR020167A1 (es) Metodo para la prevencion del inicio del asma
RU2021106904A (ru) КОМБИНАЦИИ ИНГИБИТОРОВ TGFβ И ИНГИБИТОРОВ CDK ДЛЯ ЛЕЧЕНИЯ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
NC Cough mixtures.
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired